

	Our study (N = 87)	Kishikawa's study (N =82 )
Age(years), mean(median)	68.1(67)	55.7(54)
SEX(% , female)	77	80
Disease duration <1 year (%)	0*	73
Medication(% , include duplication)		
csDMARDs	87	28
b-DMARDs	0	2
steroid	49	N.T
non treatment	6	71
Severe complication (%)	25	0
RF positive(%)	79	74
Disease activity DAS28-CRP, mean(range)	4.02 (2.01-6.36)	4.04 (1.08-6.67)
Stage(I /II /III /IV)	4 /35/36/12	58 /18 /3/ 3

**Online supplementary Table S1. Demographic data of our study and Kishikawa's study.**

csDMARDs, Conventional synthetic disease-modifying antirheumatic drugs; b-DMARDs: Biological DMARDs;

DAS28-CRP: Disease activity score with 28 joint counts (C-reactive protein); RF: Rheumatoid factor;

Stage: Steinbrocker classification of the joint X-rays; \* mean  $\pm$  standard deviation: 136  $\pm$  91 months